How all-type dementia risk factors and modifiable risk interventions may be relevant to the first-generation aging with HIV infection?
- 24 Downloads
The purpose of this review is to provide an overview of established risk factors for all-type dementia and results of interventions on dementia modifiable risk factors, all with relevance to aging people living with HIV (PLHIV).
Narrative literature review.
Our review identifies a high prevalence of risk factors for dementia in the global HIV population that is entering dementia age range (60 +), in relation to both traditional and HIV-specific risk factors. This includes age (HIV-related premature aging and possibly HIV-related accelerated brain aging and cerebrovascular injury), HIV-related and non-HIV-related cardiovascular diseases burden with related-vascular brain damage, HIV-associated neurocognitive disorders, high mental health burden, low educational/socio-economic status, historical immune compromise, and persistent immune activation with consequent augmented immune senescence. Our review highlights that the results of interventions on all-type dementia modifiable factors show discrepancies between positive observational study results and inconclusive clinical trials. The main reasons for such discrepancies relate to the preventative framework that complex interventions’ trials have difficulty to emulate and the suboptimal measurement of cognitive change. Multi-domain intervention trials are now advocated to concomitantly tackle complex age-related comorbid profiles.
The burden of dementia risk in aging PLHIV is higher than that in the general population, particularly in the most vulnerable clusters. Epidemiological studies are urgently needed to provide accurate estimates. Lessons from interventions trials in all-type dementia on modifiable factors need to be carefully considered for enhancing trials’ potential in aging PLHIV. A comprehensive and preventative neurogeriatric healthcare response linked with HIV communities and dementia associations should be urgently put in place.
KeywordsHIV/AIDS Dementia Risk factors Aging HIV-associated neurocognitive disorders Interventions Dementia modifiable risk factors
We thank our research participants for their invaluable contribution to our NeuroHIV research program.
HLA reviewed research in HIV and aging and primarily contributed to this section and to the last version of the manuscript, SK contributed to the dementia risk factors and healthy aging recommendations’ sections, TMG drafted part of an early version of the manuscript, contributed to the dementia risk factors’ section and contributed to the last version of the manuscript, BJB reviewed and contributed to the last version of the manuscript, LAC determine the review structures and focus, and contributed to all manuscripts versions.
NHMRC project grants (APP568746; CIA/PI Cysique, APP1105808 CIA/PI Brew) and NHMRC Career Development Fellowship (APP1045400; CIA/PI Cysique), Peter Duncan Neuroscience Research Unit at St. Vincent’s Centre for Applied Medical Research (St. Vincent’s Hospital, Sydney; Director: Prof. Brew).
Compliance with ethical standards
Conflict of interest
The authors report no conflicts of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
For this type of study formal consent is not required.
- 6.UNAIDS (2017) HIV and Ageing. Switzerland: UNAIDSGoogle Scholar
- 14.Europe ECfDPaCWROf (2017) HIV/AIDS surveillance in Europe 2017–2016 data. StockholmGoogle Scholar
- 17.Brothers TD, Kirkland S, Theou O, Zona S, Malagoli A, Stentarelli C et al (2014) Exploring aging trajectories among people with HIV and a general community-based cohort: transitions in health status and risk of death. Reviews in Antiviral Therapy & Infectious Diseases 7Google Scholar
- 29.Cysique LA, Brew BJ. Vascular Cognitive Impairment and HIV-Associated Neurocognitive Disorder: A New Paradigm. J Neurovirol. In PressGoogle Scholar
- 36.Sharp M. The unintended consequences of AIDS survivalGoogle Scholar
- 53.Sachdev PS, Lipnicki DM, Kochan NA, Crawford JD, Rockwood K, Xiao S et al (2013) COSMIC (Cohort Studies of Memory in an International Consortium): an international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethnic and sociocultural groups. BMC Neurol. 13(165):165CrossRefPubMedPubMedCentralGoogle Scholar
- 63.Alzheimer’s Disease International (2014) World Alzheimer’s report: Dementia and risk reduction: an analysis of protective and modifiable factors https://www.alz.co.uk/research/world-report-2014. London: Alzheimer’s disease International (AdI)
- 67.Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC et al (2014) Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med. 174(3):324–333CrossRefPubMedPubMedCentralGoogle Scholar
- 72.Post G (2013) HIV infection and the risk of acute myocardial infarction. US News & World Report (versions also appeared in MSN, Health24, MentalHelp, and 12 other publications)Google Scholar
- 73.Dorjee K, Choden T, Baxi SM, Steinmaus C, Reingold AL (2018) Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: a systematic review and meta-analyses of results from 17 epidemiologic studies. Int J Antimicrob Agents 52(5):541–553CrossRefPubMedGoogle Scholar
- 76.Grinspoon SK (2014) Perspective cardiovascular disease in HIV: traditional and nontraditional risk factors. Topics Antiviral Med 22(4):676Google Scholar
- 78.Freiberg MS, Chang CH, Skanderson M, Patterson OV, DuVall SL, Brandt CA et al (2017) Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the veterans aging cohort study. JAMA Cardiol. 2(5):536–546CrossRefPubMedPubMedCentralGoogle Scholar
- 80.Moulignier A, Savatovsky J, Assoumou L, Lescure FX, Lamirel C, Godin O et al (2018) Silent cerebral small-vessel disease is twice as prevalent in middle-aged individuals with well-controlled, combination antiretroviral therapy-treated human immunodeficiency virus (HIV) than in HIV-uninfected individuals. Clin Infect Dis. 66(11):1762–1769CrossRefPubMedGoogle Scholar
- 91.McDonald K, Elliott J, Saugeres L (2013) Ageing with HIV in Victoria: findings from a qualitative study. HIV Aust 11(2):13Google Scholar
- 101.Lipnicki DM, Crawford JD, Dutta R, Thalamuthu A, Kochan NA, Andrews G et al (2017) Age-related cognitive decline and associations with sex, education and apolipoprotein E genotype across ethnocultural groups and geographic regions: a collaborative cohort study. PLoS Med 14(3):e1002261CrossRefPubMedPubMedCentralGoogle Scholar
- 106.Cysique LA, Heaton RK, Kamminga J, Lane T, Gates TM, Moore DM et al (2014) HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research. J Neurovirol. 20(3):258–268CrossRefPubMedPubMedCentralGoogle Scholar
- 108.Pfefferbaum A, Zahr NM, Sassoon SA, Kwon D, Pohl KM, Sullivan EV (2018) Accelerated and premature aging characterizing regional cortical volume loss in human immunodeficiency virus infection: contributions from alcohol, substance use, and hepatitis C coinfection. Biol Psychiatry Cogn Neurosci Neuroimaging. 3(10):844–859CrossRefPubMedGoogle Scholar
- 111.Cole JH, Caan MWA, Underwood J, De Francesco D, van Zoest RA, Wit F et al (2018) No evidence for accelerated aging-related brain pathology in treated human immunodeficiency virus: longitudinal neuroimaging results from the comorbidity in relation to AIDS (COBRA) project. Clin Infect Dis 66(12):1899–1909CrossRefPubMedGoogle Scholar
- 129.Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK et al (2014) Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 59(9):e96–e138CrossRefPubMedPubMedCentralGoogle Scholar
- 130.Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK et al (2015) Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 60(4):627–638CrossRefPubMedGoogle Scholar
- 132.Liyanage SI, Santos C, Weaver DF (2018) The hidden variables problem in Alzheimer’s disease clinical trial design. Alzheimers Dement (NY). 4:628–635Google Scholar
- 140.Levin J. Aging of HIV-Infected: a explosive and underestimated phenomena being ignored, needs attention—special support services for patients & clinics needed-lack of federal/state response—HCV too—Commentary by Jules Levin. Community Perspectives: “A call to action: What should our research, care, education and social support priorities be?” http://www.natap.org/2017/HIV/040417_01.htm2018
- 142.Terpstra AR, Worthington C, Ibanez-Carrasco F, O’Brien KK, Yamamoto A, Chan Carusone S et al (2018) I’m Just Forgetting and I Don’t Know Why”: exploring how people living with HIV-associated neurocognitive disorder view, manage, and obtain support for their cognitive difficulties. Qual Health Res 28(6):859–872CrossRefPubMedGoogle Scholar